“…At present, studies in humans and animals have shown that protection by vaccination is possible. Potential candidates for Shigella vaccines include glycoconjugate vaccines, such as recombinant glycoconjugate, synthetic glycoconjugate, O -polysaccharide covalently linked to immunogenic carrier proteins,177,178 virG-based live attenuated (WRSS1, WRSs3, WRSf3, WRSf2G12, WRSf2G15and WRSd1),179,180 recombinant outer-membrane proteins,181 live attenuated vaccines,182,183 invasion-plasmid antigens B, C, and D,184 DNA-based vaccines, Ty21a typhoid vaccine expressing Shigella LPS,185 recombinant probiotic–based candidates,186 and whole-cell-killed and Shigella trivalent inactivated whole-cell and heat-killed multiserotype Shigella ,187,188 as well as novel antigen candidates, such as triacylated S-LPS, subcellular complexes purified from virulent cultures (Invaplex),189 GMMA protein particles,190 and an OMV-NP vaccine (Table 3). 191…”